Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)
This is a treatment use study to provide early access to MK0518 for the treatment of HIV-1 infection in patients who have limited or no treatment options due to virological failure, resistance, or intolerance to multiple antiretroviral regimens. Enrollment in this study is patient driven. Investigators are not proactively assigned. There is no target sample size and duration of the study is indefinite. For information on how to enroll in the study, see link below.
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00377065
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|